ClinicalTrials.gg
CompletedNCT02192749Updated Oct 13, 2017

Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism

A Phase 1/2 interventional study of Umbilical cord mesenchymal stem cells in Autism, sponsored by Translational Biosciences. Completed at 1 site in Panama. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2017-10-13.

Sponsored by Translational Biosciences · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
6 Years to 16 Years
Sex
All
01

Study summary

Allogeneic (not from the subject) human umbilical cord tissue-derived stem cells administered intravenously (IV) in a series of 4 infusions every 3 months over the course of one year is safe and will induce a therapeutic effect in autism patients.

02

Conditions studied

  • Autism

Browse trials for

Keywords

  • autism
  • umbilical cord
  • mesenchymal
  • stem cells
03

In context

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

This study's enrollment of 20 is below the median of 49 across 813 interventional studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

Translational Biosciences is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female
  • Ages 6 to 16
  • (DSM IV) diagnosis of autism confirmed by Autism Diagnostic Observation Schedule (ADOS) and/or Autism Diagnostic Interview-Revised (ADI-R)
  • No anticipated changes in treatment for the study duration (e.g., diet, nutrients)
  • No additional biomedical treatments started 6 weeks prior to enrollment
  • No changes in dietary management for 3 months prior to enrollment
  • Ambulatory or require minimum support walking, per parent
  • Able to sit still for 5 minutes or longer with a preferred toy item, per parent
  • Adequate vision and hearing for the purposes of test administration, per parent
  • Adequate arm-hand-finger coordination (i.e., able to point) for learning and cognitive tasks used in outcome measurement, per parent
  • Stable and controlled mental disorder
  • Under the care of a caregiver willing to participate by attending regularly scheduled appointments and completing the necessary measures
  • Normal heavy metals test for lead and mercury levels performed within 30 days of first stem cell infusion
  • Must provide name and specialty of specialist who has made Autism Spectrum Disorder (ASD) diagnosis
  • Adequate financial means to cover $7,200 (US Dollars) plus travel expenses

Exclusion criteria

Exclusion Criteria:

  • Significant prematurity at birth (less than 32 weeks gestation); or birth weight significantly below normal for gestational age (SGA - small for gestational age)
  • mental retardation
  • seizure disorder
  • auto-immune conditions
  • history of head trauma and other neurological or medical conditions
  • Abnormal heavy metals test for lead and mercury performed within 30 days of first stem cell infusion
  • Prior stem cell therapy of any kind
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Umbilical cord mesenchymal stem cells

    Biological: Umbilical cord mesenchymal stem cells

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    Time frame: 89 weeks

Secondary outcomes

  1. Number of participants with a change in disability as measured by the Autism Treatment Evaluation Checklist (ATEC)

    Time frame: 13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks

  2. Number of participants with a change in disability as measured by the Childhood Autism Rating Scale (CARS)

    Time frame: 13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks

  3. Change from baseline macrophage-derived chemokine (MDC)

    Time frame: 13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks

  4. Change from baseline thymus and activation-regulated chemokine (TARC)

    Time frame: 13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks

07

Study locations

1 site
  • Stem Cell Institute
    Panama City, Panama
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2014
First posted
Jul 17, 2014
Start
Jul 2014
Primary completionActual
Aug 2017
CompletionActual
Aug 2017
Last update
Oct 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02192749
Lead sponsor
Translational Biosciences
Responsible party
Sponsor
First posted
Jul 17, 2014
Start date
Jul 2014
Primary completion
Aug 2017
Completion
Aug 2017
Last update
Oct 13, 2017

Study contacts

Nelson Novarro, MD
principal investigator
Jorge Paz-Rodriguez, MD
principal investigator · Translational Biosciences / Stem Cell Institute Panama

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion